Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases


Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.blueprintmedicines.com

Recent News

May 17, 2017
Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting

May 3, 2017
Blueprint Medicines Reports First Quarter 2017 Financial Results

April 26, 2017
Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017

Read More News

Associated Team Members

Alexis Borisy
Partner

Neil Exter
Partner